EarlyScreenDx is pioneering a new generation of point-of-care cancer detection kits powered by proprietary biomarker technology that identifies cancerous and precancerous tissue with a simple colorimetric reaction.
EarlyScreenDx is a diagnostics company built on one conviction: cancer detected early saves lives. We are translating cutting-edge biomarker science into accessible, affordable screening tools that can reach patients before symptoms appear.
Founded by a team spanning oncology, molecular biology, and healthcare operations, we are developing our flagship colon cancer detection kit in collaboration with leading Indian biotech partners, with breast and lung cancer screening kits already in the roadmap.
To make cancer screening as routine as a blood pressure check, empowering millions to catch the disease at its most treatable stage.
We combine proprietary biomarker discovery with simple colorimetric chemistry, enabling results that are readable without complex laboratory equipment.
Our development partnership with Imgenex Pvt Ltd, Bhubaneswar accelerates manufacturing scale-up and quality validation.
Our patented platform detects a unique biomarker expressed in cancerous and precancerous tissue and turns it into colour you can see.
A proprietary biomarker expressed specifically in cancerous and precancerous colorectal tissue is targeted by our detection system. The biomarker is absent in healthy tissue, providing high specificity.
Patients provide a simple, non-invasive sample at the point of care using our collection kit. No bowel prep, no sedation, and no complex laboratory infrastructure required.
When the sample contacts our proprietary reagents, a colorimetric reaction occurs exclusively in the presence of the cancer biomarker, producing a visible colour change that indicates a positive result.
Our intellectual property covers both the biomarker target and the reagent system, creating a defensible, first-mover advantage across multiple cancer types.
Positive results are followed by confirmatory clinical diagnostics. Our system is designed as a population-level first screen, safe, scalable, and actionable.
Live Reaction Demo
Sample
Reagent
Result
Colour change indicates biomarker presence
Our lead product. Kit validation underway in collaboration with Imgenex. Targeting launch as India's first point-of-care colorectal cancer screening kit.
Biomarker candidates identified. Early feasibility studies planned. Leveraging platform reagent chemistry developed for colorectal indication.
Stage-gate planned post breast-cancer feasibility. Target to build a comprehensive early detection portfolio addressing India's top cancer burden.
Our founders bring together expertise in molecular biology, oncology, and business strategy to translate a breakthrough technology into a scalable healthcare solution.
Visionary leader driving EarlyScreenDx's strategic direction, investor relations, and commercial growth. Committed to making early cancer detection accessible across India and beyond.
Oversees organisational leadership and partnership development. Brings deep expertise in healthcare operations and stakeholder management to scale the company's mission.
Our advisory board brings decades of experience in drug discovery, venture building, and cancer biology from leading global institutions.
Director of Cardiovascular at Flagship Pioneering. Nearly a decade of drug discovery experience across oncology, cardiovascular, and infectious diseases. Co-inventor of Camzyos, the first-in-class FDA-approved therapy for hypertrophic cardiomyopathy. Co-founder of Kainomyx Inc. PhD from TIFR India; postdoctoral fellow at Stanford University. Published in Science, Nature, and PNAS.
Deep-tech venture builder with a proven track record across biotech, AI, and deep tech. Instrumental in raising over $75M in venture funding, structuring strategic partnerships, and driving startup growth from launch through commercial scale.
Former Vice Provost and Dean at UMBC and postdoctoral fellow at the National Cancer Institute, NIH. Research focused on cell cycle regulation and malignant transformation in lung and liver cancers. Senior leadership spanning the University of Maryland School of Medicine, USF, and the University of Tampa.
EarlyScreenDx is proud to be incubated at one of India's most prestigious life sciences incubators, providing access to world-class infrastructure, mentorship, and an ecosystem of scientists, clinicians, and investors.
We welcome conversations with clinicians, investors, healthcare systems, and research institutions who share our vision for accessible early cancer detection.
Ready to connect?
Fill out our contact form and a member of the EarlyScreenDx team will get back to you shortly.
Get In Touch ↗